N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
|
|
|
- CAS號:
- 133825-80-6
- 英文名:
- N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
- 英文別名:
- ATR-101;PD-132301;Nevanimibe (ATR-101);ATR 101; ATR101; PD-132301;1-(2,6-Diisopropylphenyl)-3-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea;N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea;Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-
- 中文名:
- N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
- 中文別名:
- 化合物 T12225;化合物 NEVANIMIBE;1-(2,6-二異丙基苯基)-3-((1-(4-二甲胺基)苯基)環(huán)戊基)甲基)脲
- CBNumber:
- CB31327866
- 分子式:
- C27H39N3O
- 分子量:
- 421.62
- MOL File:
- 133825-80-6.mol
|
|
|
N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea化學(xué)性質(zhì)
-
沸點:
-
528.1±50.0 °C(Predicted)
-
|
-
密度:
-
1.062±0.06 g/cm3(Predicted)
-
|
-
儲存條件:
-
2-8°C
-
|
-
酸度系數(shù)(pKa):
-
13.91±0.46(Predicted)
-
|
N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea性質(zhì)、用途與生產(chǎn)工藝
Nevanimibe (PD-132301) 是一種口服有效的，選擇性酰基輔酶 A：膽固醇 O-?；D(zhuǎn)移酶 1 (ACAT1) 抑制劑，EC50 為 9 nM。Nevanimibe 抑制 ACAT2，EC50 為 368 nM。Nevanimibe 誘導(dǎo)細胞凋亡 (apoptosis)，并具有抗腎上腺皮質(zhì)癌的潛力。
|
ACAT1
9 nM (EC
50
)
|
ACAT2
368 nM (EC
50
)
|
Coincubation of Nevanimibe (PD-132301; ATR101; 3 nM-30 μM) and Cholesterol markedly increases toxicity in a dose-dependent manner, where 3 nM Nevanimibe in the presence of 60 μg/mL Cholesterol reduces survival by 60% after 24 hours. All doses of Nevanimibe (3 nM-30 μM) induces cytoxicity in the presence of Cholesterol, whereas treatment with Cholesterol in the absence of Nevanimibe has no effect on cell viability.
Cell Cytotoxicity Assay
|
Cell Line:
|
The H295R and HAC clone 15 (HAC15) human ACC cell lines
|
|
Concentration:
|
3 nM-30 μM
|
|
Incubation Time:
|
24 hours
|
|
Result:
|
3 nM-3 μM exhibited no toxicity, whereas 30 μM treatment reduced survival by approximately 40% within 24 hours.
|
N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2026/06/05 | HY-100399 | N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
Nevanimibe | 133825-80-6 | 5 mg | 1000元 |
| 2026/06/05 | HY-100399 | N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
Nevanimibe | 133825-80-6 | 10 mM * 1 mL in DMSO | 1100元 |
N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea
生產(chǎn)廠家
133825-80-6, N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea 相關(guān)搜索:
- 抑制劑
- 化合物 NEVANIMIBE
- 化合物 T12225
- 1-(2,6-二異丙基苯基)-3-((1-(4-二甲胺基)苯基)環(huán)戊基)甲基)脲
- 133825-80-6
- Nevanimibe (ATR-101)
- ATR 101; ATR101; PD-132301
- PD-132301
- Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-
- 1-(2,6-Diisopropylphenyl)-3-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea
- ATR-101
- N-(2,6-bis(isopropyl)phenyl)-N'-((1-(4-(dimethylaminomethyl)phenyl)cyclopentyl)methyl)urea